PTC Therapeutics (PTCT) vs Recursion Pharmaceuticals (RXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
PTC Therapeutics (PTCT) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, losing 2.0% versus a loss of 26.2%. Over five years, PTCT leads with a +69.9% price change compared with -77.1% for RXRX. PTC Therapeutics is the larger company by market cap ($5.40 billion vs $2.34 billion), about 2.3 times the size.
PTC Therapeutics converts more of its revenue into profit, with a net margin of 39.4% versus -863.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PTCT | RXRX |
|---|---|---|
| Share price | $64.70 | $4.36 |
| Market cap | $5.40B | $2.34B |
| 1-day change | +3.42% | +10.38% |
| YTD return | -14.82% | +6.60% |
| 1-year return | -1.98% | -26.23% |
| 5-year return | +69.86% | -77.10% |
| Forward P/E | 27.30 | — |
| EPS (TTM) | $-0.67 | $-1.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.73B | $74.68M |
| Revenue growth (YoY) | +114.51% | +26.92% |
| Net income (latest FY) | $682.64M | $-644.76M |
| Gross margin | — | 4.99% |
| Operating margin | 50.09% | -867.87% |
| Net margin | 39.44% | -863.35% |
| 52-week high | $90.87 | $7.18 |
| 52-week low | $61.23 | $2.77 |
| Distance from 52-week high | -28.80% | -39.28% |
| Analyst consensus | buy | none |
| Avg. price target upside | +56.21% | +65.60% |
| Average volume | 1.14M | 20.93M |
| Shares outstanding | 83.46M | 535.34M |
| Employees | 991 | 600 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTC Therapeutics is about 2.3 times larger than Recursion Pharmaceuticals by market value ($5.40B vs $2.34B).
- PTCT has outperformed RXRX by 24.2 percentage points over the past year.
- PTC Therapeutics is more profitable, keeping 39.4 cents of every revenue dollar as net income versus -863.4 cents for Recursion Pharmaceuticals.
- PTC Therapeutics grew revenue faster in its latest fiscal year (+114.51% vs +26.92%).
About PTC Therapeutics
PTCT stock →PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 991 employees
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
PTCT vs RXRX FAQ
Which is bigger, PTC Therapeutics or Recursion Pharmaceuticals?
PTC Therapeutics (PTCT) is larger, with a market capitalization of $5.40B compared with $2.34B for Recursion Pharmaceuticals (RXRX).
Which stock has performed better over the past year, PTCT or RXRX?
PTCT returned -1.98% over the past 12 months, compared with -26.23% for RXRX (price return, excluding dividends). Past performance does not predict future results.
Are PTC Therapeutics and Recursion Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for PTC Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Recursion Pharmaceuticals.